Table 2.

Experimental Design.

Media	timepoint	Donors (Human samples)								Animals
		H1	H26	H27	H29	TX06	TX08	TX25	Total	M1-M5
CTR	24 h	1	1	1	1	1	1	1	7	5
	48 h	0*	1	1	1	1	1	1	6	5
G	24 h	1	1	1	1	1	1	1	7	5
	48 h	1	1	1	1	0**	1	0**	5	5
F	24 h	1	1	1	1	1	1	1	7	5
	48 h	1	1	1	1	0**	1	1	6	5
GF	24 h	1	1	1	1	1	1	1	7	5
	48 h	1	1	1	1	0**	1	1	6	5
GFI	24 h	1	1	1	1	1	1	1	7	5
	48 h	1	1	1	1	0**	1	1	6	5
GFIO	24 h	0*	1	1	1	1	1	0*	5	5
	48 h	1	1	1	1	1	1	0*	6	5
GFIP	24 h	1	1	1	1	1	1	1	7	5
	48 h	1	1	1	1	1	1	1	7	5
GFIPO	24 h	1	1	1	1	0*	0**	0**	4	5
	48 h	1	1	1	1	0*	1	1	6	5
Total		14	16	16	16	10	15	12	99	80

Sample and experimental overview. For the human study we used PCLSs from 7 human donors which have been incubated across 2 × 8 assay conditions giving a total of 112 samples. For 6 samples, the PCLSs were not suitable for RNA preparation (indicated by *). The remaining 106 samples have been processed and sequenced of which 7 samples have been identified as outliers and discarded from further analysis (indicated by **). For the mouse study we used fresh livers from five animals, which gives a total number of 16 × 5 = 80 samples. To yield enough material, three slices per sample condition have been incubated together. All mouse samples have been included. We prepared eight different media i.e. CTR: Control with 25 mM Glucose, G: 36 mM Glucose, F: 25 mM Glucose + 5 mM Fructose, GF: 36 mM Glucose + 5 mM Fructose, GFI: GF + 1 nM Insulin, GFIO: GFI + 480 μM Oleic acid, GIP: GFI + 240 μΜ Palmitic acid, GFIPO: GFI + 480 μΜ Oleic acid + 240 μΜ Palmitic acid) and cultured PCLSs from each donor for 24 h and 48 h.